» Articles » PMID: 19324256

Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction: a Community-based Study

Overview
Date 2009 Mar 28
PMID 19324256
Citations 389
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study sought to define the prevalence, severity, and significance of pulmonary hypertension (PH) in heart failure with preserved ejection fraction (HFpEF) in the general community.

Background: Although HFpEF is known to cause PH, its development is highly variable. Community-based data are lacking, and the relative contribution of pulmonary venous versus pulmonary arterial hypertension (HTN) to PH in HFpEF is unknown. We hypothesized that PH would be a marker of symptomatic pulmonary congestion, distinguishing HFpEF from pre-clinical hypertensive heart disease.

Methods: This community-based study of 244 HFpEF patients (age 76 +/- 13 years; 45% male) was followed up using Doppler echocardiography over 3 years. Control subjects were 719 adults with HTN without HF (age 66 +/- 10 years; 44% male). Pulmonary artery systolic pressure (PASP) was derived from the tricuspid regurgitation velocity and PH defined as PASP >35 mm Hg. Pulmonary capillary wedge pressure (PCWP) was estimated from the ratio of early transmitral flow velocity to early mitral annular diastolic velocity.

Results: In HFpEF, PH was present in 83% and the median (25th, 75th percentile) PASP was 48 (37, 56) mm Hg. PASP increased with PCWP (r = 0.21; p < 0.007). Adjusting for PCWP, PASP was higher in HFpEF than HTN (p < 0.001). The PASP distinguished HFpEF from HTN with an area under the receiver-operating characteristic curve of 0.91 (p < 0.001) and strongly predicted mortality in HFpEF (hazard ratio: 1.3 per 10 mm Hg; p < 0.001).

Conclusions: PH is highly prevalent and often severe in HFpEF. Although pulmonary venous HTN contributes to PH, it does not fully account for the severity of PH in HFpEF, suggesting that a component of pulmonary arterial HTN also contributes. The potent effect of PASP on mortality lends support for therapies aimed at pulmonary arterial HTN in HFpEF.

Citing Articles

Macitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension Study.

Shah S, Bonderman D, Borlaug B, Cleland J, Lack G, Lu W Circ Heart Fail. 2025; :e011381.

PMID: 40066571 PMC: 11905905. DOI: 10.1161/CIRCHEARTFAILURE.123.011381.


Towards a phenotype profiling of the patients with heart failure and preserved ejection fraction.

Bonfioli G, Pagnesi M, Calo L, Metra M Eur Heart J Suppl. 2025; 27(Suppl 1):i115-i121.

PMID: 39980782 PMC: 11836726. DOI: 10.1093/eurheartjsupp/suae095.


The right ventricle: the co-star in the complex history of heart failure.

Manzi G, Recchioni T, Mihai A, Severino P, Birtolo L, Filomena D Eur Heart J Suppl. 2025; 27(Suppl 1):i109-i114.

PMID: 39980774 PMC: 11836718. DOI: 10.1093/eurheartjsupp/suae092.


Identification of digital twins to guide interpretable AI for diagnosis and prognosis in heart failure.

Gu F, Meyer A, Jezek F, Zhang S, Catalan T, Miller A NPJ Digit Med. 2025; 8(1):110.

PMID: 39966509 PMC: 11836287. DOI: 10.1038/s41746-025-01501-9.


The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF).

Hullon D, Subeh G, Volkova Y, Janiec K, Trach A, Mnevets R Cardiovasc Diabetol. 2025; 24(1):70.

PMID: 39920668 PMC: 11806760. DOI: 10.1186/s12933-025-02607-w.


References
1.
McGoon M, Gutterman D, Steen V, Barst R, McCrory D, Fortin T . Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126(1 Suppl):14S-34S. DOI: 10.1378/chest.126.1_suppl.14S. View

2.
Klapholz M, Maurer M, Lowe A, Messineo F, Meisner J, Mitchell J . Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol. 2004; 43(8):1432-8. DOI: 10.1016/j.jacc.2003.11.040. View

3.
Abramson S, Burke J, KELLY Jr J, Kitchen 3rd J, Dougherty M, Yih D . Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med. 1992; 116(11):888-95. DOI: 10.7326/0003-4819-116-11-888. View

4.
Oh J, Hatle L, Tajik A, Little W . Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. J Am Coll Cardiol. 2006; 47(3):500-6. DOI: 10.1016/j.jacc.2005.09.032. View

5.
Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P . Recommendations for chamber quantification. Eur J Echocardiogr. 2006; 7(2):79-108. DOI: 10.1016/j.euje.2005.12.014. View